Form 4: Wave Life Sciences CEO Sells Shares Under 10b5-1 Plan

Wave Life Sciences Ltd. President and CEO Paul Bolno sold 217,351 ordinary shares for a weighted-average price of $10.098 per share, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Paul Bolno, President and CEO of Wave Life Sciences Ltd., disposed of 217,351 ordinary shares.
• The transaction occurred on August 22, 2025.
• The shares were sold at a weighted-average price of $10.098 per share, with individual sale prices ranging from $10.00 to $10.27.
• The sale was executed under a Rule 10b5-1 trading plan, which was adopted by Mr. Bolno on May 19, 2025.
• Following this transaction, Mr. Bolno directly beneficially owns 121,000 ordinary shares.

Sentiment

Score: 5

Explanation: The filing reports a pre-scheduled insider share sale under a 10b5-1 plan, which is a routine disclosure and does not inherently indicate positive or negative sentiment regarding the company's operational performance or future prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine disclosure of an insider transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale by a key executive, even if pre-planned, could be viewed with scrutiny by some investors, though a 10b5-1 plan typically mitigates concerns about opportunistic selling.

Key Dates

Keywords

Wave Life Sciences, WVE, Paul Bolno, Insider Trading, Form 4, Share Sale, 10b5-1 Plan, Executive Compensation